metoprolol has been researched along with Parkinson Disease in 4 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "To verify the previously reported association between long-term use of β2-adrenoreceptor (β2AR) agonist and antagonist with reduced and increased risk of Parkinson disease (PD), respectively." | 1.51 | Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease. ( Blaabjerg, M; Christensen, K; Deuschl, G; Höglinger, GU; Hopfner, F; Kuhlenbäumer, G; Pottegård, A; Rösler, TW; Wod, M, 2019) |
| "Metoprolol (MP) was given intravenously to reduce blood pressure during surgery." | 1.35 | Noradrenergic modulation of subthalamic nucleus activity in human: metoprolol reduces spiking activity in microelectrode recordings during deep brain stimulation surgery for Parkinson's disease. ( Abdel Rahman, A; Castro-Prado, F; Coenen, VA; Gielen, FL; Honey, CR, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hopfner, F | 1 |
| Wod, M | 1 |
| Höglinger, GU | 1 |
| Blaabjerg, M | 1 |
| Rösler, TW | 1 |
| Kuhlenbäumer, G | 1 |
| Christensen, K | 1 |
| Deuschl, G | 1 |
| Pottegård, A | 1 |
| Coenen, VA | 1 |
| Gielen, FL | 1 |
| Castro-Prado, F | 1 |
| Abdel Rahman, A | 1 |
| Honey, CR | 1 |
| de Milliano, PA | 1 |
| van Eck-Smit, BL | 1 |
| de Groot, AC | 1 |
| Lie, KI | 1 |
| Allman, KC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of alpha1- Adrenergic Receptor Antagonist Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease: A Follow up Study[NCT05109364] | Phase 2 | 15 participants (Anticipated) | Interventional | 2022-09-23 | Recruiting | ||
| The Effect of Adrenergic Blocker Therapy on Cardiac and Striatal Transporter Uptake in Pre-Motor and Symptomatic Parkinson's Disease[NCT03775096] | Phase 2 | 15 participants (Anticipated) | Interventional | 2019-04-04 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for metoprolol and Parkinson Disease
| Article | Year |
|---|---|
Use of β2-adrenoreceptor agonist and antagonist drugs and risk of Parkinson disease.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Adrenergic beta-Agonists; Adrenergic beta-Antag | 2019 |
Noradrenergic modulation of subthalamic nucleus activity in human: metoprolol reduces spiking activity in microelectrode recordings during deep brain stimulation surgery for Parkinson's disease.
Topics: Adrenergic beta-Antagonists; Aged; Antihypertensive Agents; Deep Brain Stimulation; Electroencephalo | 2008 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Anti-Arrhythmia Agents; Autonomic Nervous System Diseases; Heart; Humans; Hyp | 2000 |
Metoprolol-induced changes in myocardial (123)I-metaiodobenzylguanidine uptake in Parkinson's disease.
Topics: 3-Iodobenzylguanidine; Heart; Humans; Hypotension, Orthostatic; Iodine Radioisotopes; Metoprolol; My | 2001 |